HistoRx Inc.
This article was originally published in Start Up
Executive Summary
Aiming to move pathology into the molecular age, HistoRx Inc. will use its tissue-analysis algorithms, termed AQUA, to automate quantitative analysis of proteins in tissue samples for drug discovery and development. Eventually, HistoRx wants to use its reagents and in situ diagnostic instrumentation and software to replace the clinical pathologist's eye for biomarker analysis.
You may also be interested in...
The A-List: 2004's Trend-Shaping Series A Financings
Analyzing the venture financings closed by 2004's new crop of biotech, diagnostics, and medical device start-ups reveals today's trends that may shape tomorrow's health care industry. Here we point out eleven 2004 Series A financings that identify and illustrate what's hot.
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.